TABLE IV.
Most common chemotherapy regimens by cancer and g-csf administered
| Regimena |
Patient groupb
|
|||||
|---|---|---|---|---|---|---|
| Filgrastim (n=286) | Pegfilgrastim (n=109) | Overall (N=395) | ||||
|
|
|
|
||||
| (n) | (%) | (n) | (%) | (n) | (%) | |
| Breast cancer | 163 | 100.0 | 68 | 100.0 | 231 | 100.0 |
| fec-d | 54 | 33.1 | 26 | 38.2 | 80 | 34.6 |
| tc | 36 | 22.1 | 12 | 17.6 | 48 | 20.8 |
| fec | 13 | 8.0 | 10 | 14.7 | 23 | 10.0 |
| tch | 12 | 7.4 | 1 | 1.5 | 13 | 5.6 |
| tac | 13 | 8.0 | 0 | 0.0 | 13 | 5.6 |
| Colorectal cancer | 26 | 100.0 | 5 | 100.0 | 31 | 100.0 |
| folfox6 | 9 | 34.6 | 3 | 60.0 | 12 | 38.7 |
| folfox4 | 8 | 30.8 | 1 | 20.0 | 9 | 29.0 |
| folfox | 3 | 11.5 | 0 | 0.0 | 3 | 9.7 |
| folfiri | 2 | 7.7 | 4 | 80.0 | 6 | 19.4 |
| Lung cancer | 8 | 100.0 | 1 | 100.0 | 9 | 100.0 |
| Cisplatin–vinblastine | 4 | 50.0 | 0 | 0.0 | 4 | 44.4 |
| Carboplatin–epirubicin | 2 | 25.0 | 0 | 0.0 | 2 | 22.2 |
| Gemcitabine–carboplatin | 2 | 25.0 | 0 | 0.0 | 2 | 22.2 |
| Epirubicin–cisplatin | 0 | 0.0 | 1 | 100.0 | 1 | 11.1 |
| Hodgkin lymphoma | 23 | 100.0 | 4 | 100.0 | 27 | 100.0 |
| abvd | 21 | 91.3 | 4 | 100.0 | 25 | 92.6 |
| gdp | 1 | 4.3 | 0 | 0.0 | 1 | 3.7 |
| chop-r | 1 | 4.3 | 0 | 0.0 | 1 | 3.7 |
| Non-Hodgkin lymphoma | 36 | 100.0 | 8 | 100.0 | 44 | 100.0 |
| chop-r | 28 | 77.8 | 7 | 87.5 | 35 | 79.5 |
| chop | 2 | 5.6 | 1 | 12.5 | 3 | 6.8 |
| dhap | 2 | 5.6 | 0 | 0.0 | 2 | 4.5 |
| cvp-r | 2 | 5.6 | 0 | 0.0 | 2 | 4.5 |
| Testicular cancer | 6 | 100.0 | 4 | 100.0 | 10 | 100.0 |
| bep | 6 | 100.0 | 3 | 75.0 | 9 | 90.0 |
| Epirubicin–cisplatin | 0 | 0.0 | 1 | 25.0 | 1 | 10.0 |
| Solid bone tumour | 3 | 100.0 | 10 | 100.0 | 13 | 100.0 |
| Cisplatin–doxorubicin–dexamethasone | 0 | 0.0 | 2 | 20.0 | 2 | 15.4 |
| Ifosfamide–mitozantrone–dexamethasone | 0 | 0.0 | 2 | 20.0 | 2 | 15.4 |
| Ifosfamide–doxorubicin, mesna | 0 | 0.0 | 2 | 20.0 | 2 | 15.4 |
| Other solid tumour | 6 | 100.0 | 7 | 100.0 | 13 | 100.0 |
| Gemcitabine–docetaxel | 1 | 16.7 | 3 | 42.9 | 4 | 30.8 |
| Paclitaxel–carboplatin | 2 | 33.3 | 1 | 14.3 | 3 | 23.1 |
| Other hematologic cancer | 3 | 100.0 | 0 | 0.0 | 3 | 100.0 |
| Fludarabine (oral) | 1 | 33.3 | 0 | 0.0 | 1 | 33.3 |
| Fludarabine plus cytarabine | 1 | 33.3 | 0 | 0.0 | 1 | 33.3 |
| cvp-r | 1 | 33.3 | 0 | 0.0 | 1 | 33.3 |
For each cancer type, only the top 5 regimens, in order of frequency, are included.
Percentages are calculated based on the number of patients with the particular cancer type.
fec-d = fluorouracil–epirubicin–cyclophosphamide, docetaxel; tc = docetaxel–cyclophosphamide; fec = fluorouracil–epirubicin–cyclophosphamide; tch = docetaxel–carboplatin–trastuzumab; tac = docetaxel–doxorubicin–cyclophosphamide; folfox = folinic acid–fluorouracil–oxaliplatin; folfiri = folinic acid–fluorouracil–irinotecan; abvd = doxorubicin–bleomycin–vinblastine–dacarbazine; gdp = gemcitabine–dexamethasone–cisplatin; chop-r = cyclophosphamide–hydroxydaunorubicin (doxorubicin)–vincristine–prednisone, rituximab; chop = cyclophosphamide–hydroxydaunorubicin (doxorubicin)–vincristine–prednisone; dhap = dexamethasone–cytarabine–cisplatin; cvp-r = cyclophosphamide–vincristine–prednisone, rituximab; bep = bleomycin–etoposide–cisplatin; cvp-r = cyclophosphamide–vincristine–prednisone, rituximab.